Eftychia Eirini Psarelli

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · Journal of Clinical Oncology · 2020 · 164 citations

Surgical Oncology, Neoadjuvant Therapy, Cancer Management +17

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Annals of the Rheumatic Diseases · 2014 · 155 citations · Full text

Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery

Malcolm West, Rebecca Asher, Michael J. Browning et al. · British journal of surgery · 2016 · 152 citations

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux et al. · The Lancet Diabetes & Endocrinology · 2020 · 119 citations · Full text

Once-daily Nitisinone, Urological Research, Pharmacology +3